Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...

Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...

Gait Training: Techniques to improve walking ... and managing the long-term effects of ataxia and cerebellar disorders. Care To You Health provides Medicare-approved maintenance therapy programs ...

While most parents of kindergartners are worried about their kids learning to read and playing well with others, Bryan and Beth Fugere of Shakopee are worried about enrolling not just one, but two ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...

Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...

As well, systemic and geriatric disorders will complicate the findings. The following are then assessed in order: gait; signs of frontal dysfunction; signs of parkinsonism; neuroophthalmologic ...

The assessment findings in NPH include a distinctive gait abnormality and disturbances in cognition and control of urine. Some dementias, such as that caused by NPH, are treatable. Nurses and ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Feb. 5, 2025 — New research has shown that diet could influence the risk of both depression and Alzheimer's disease (AD). Evidence suggests that depressive symptoms are both a risk factor for AD ...